CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 128 enrolled
Drug / intervention
GSK561679 +1 moredrug
Likely dose
GSK561679 350mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01814332
NCT01814332Phase 2Completed
CompareCT.gov

CRF Receptor Antagonist for PTSD and Related Sleep Disturbances in Women

VA Office of Research and Development·interventional·Posted Mar 19, 2013·Updated Jun 25, 2021

In Brief

A Phase 2 clinical trial evaluating GSK561679 and Placebo for Stress Disorders, Post-traumatic. Completed, enrolled 128 participants across 1 site.

Detailed Summary

This purpose of this study is to look at the safety of the experimental drug GSK561679 as well as its effects on PTSD symptoms, thinking and memory, startle reaction, stress hormones, and mental health symptoms in comparison to placebo (an inactive substance).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStress Disorders, Post-traumatic
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 19, 2013
Enrollment StartJan 1, 2010
Primary CompletionJun 30, 2014
Study CompletionOct 31, 2014
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 13.3 years ago

Interventions

GSK561679drug

GSK561679, oral administration, 350mg/day, 6 week administration

Placebodrug

Placebo compound treatment for comparison with IP